Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

SafeLM Versus LMA Classic for Airway Management During Fibroadenoma Excision

2 oktober 2026 bijgewerkt door: Hanoi Medical University

Comparison of Airway Control Effectiveness of the SafeLM Video Laryngeal Mask and the LMA Classic in Patients Undergoing General Anesthesia for Fibroadenoma Excision

This randomized controlled trial compares the airway management performance of the SafeLM video laryngeal mask with the LMA Classic in adult patients undergoing elective fibroadenoma excision under general anesthesia. Participants will be randomly assigned to airway management with either the SafeLM or the LMA Classic. The primary outcome is oropharyngeal leak pressure. Secondary outcomes include insertion performance, ventilation parameters, hemodynamic responses, and airway-related adverse events.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

The SafeLM is a video-assisted laryngeal mask that allows visualization during placement, whereas the LMA Classic is a conventional supraglottic airway device. This study is designed to compare the clinical performance of these two devices under standardized conditions.

Adult patients scheduled for elective fibroadenoma excision under general anesthesia will be screened for eligibility. Only patients for whom both devices are considered clinically appropriate will be enrolled, thereby avoiding randomization when patient characteristics indicate a preference for a particular airway management technique. Eligible participants will be randomly assigned to airway management with either the SafeLM or the LMA Classic.

After standardized induction of general anesthesia, the assigned laryngeal mask will be inserted according to the study protocol. The primary outcome is oropharyngeal leak pressure after successful placement. Device insertion characteristics, ventilation parameters, hemodynamic responses, and airway-related adverse events will also be evaluated.

Studietype

Ingrijpend

Inschrijving (Geschat)

132

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

  • Female patients aged 18 years or older.
  • Scheduled for elective excision of benign breast fibroadenoma under general anesthesia.
  • Planned airway management with a laryngeal mask airway.
  • American Society of Anesthesiologists (ASA) physical status I-II.
  • Both the SafeLM and LMA Classic are considered clinically appropriate for airway management.
  • Provision of written informed consent.

Exclusion Criteria:

  • Increased risk of pulmonary aspiration, including inadequate preoperative fasting, full stomach, or gastrointestinal obstruction.
  • Known or suspected difficult airway or other airway characteristics for which random allocation between the two study devices is considered clinically inappropriate.
  • Upper airway pathology or anatomical abnormality that may interfere with laryngeal mask placement.
  • Clinical or surgical indication requiring tracheal intubation rather than a laryngeal mask airway.
  • Contraindication or known allergy to medications used in the standardized anesthesia protocol.
  • Inability to provide informed consent.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: SafeLM Video Laryngeal Mask

Participants randomized to this arm will receive airway management with the SafeLM video laryngeal mask during general anesthesia for elective fibroadenoma excision. The device will be inserted according to the standardized study protocol.

The SafeLM is a video-assisted supraglottic airway device that allows visualization of the laryngeal structures during insertion and positioning. It will be used for airway management during general anesthesia according to the standardized study protocol.

Actieve vergelijker: LMA Classic

Participants randomized to this arm will receive airway management with the LMA Classic during general anesthesia for elective fibroadenoma excision. The device will be inserted according to the standardized study protocol.

The LMA Classic is a conventional supraglottic airway device without video guidance. It will be used for airway management during general anesthesia according to the standardized study protocol.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Oropharyngeal Leak Pressure (OLP)
Tijdsspanne: Immediately after successful laryngeal mask placement, before the start of surgery

Oropharyngeal leak pressure will be measured after successful placement of the assigned laryngeal mask and establishment of effective ventilation. OLP will be recorded in cmH2O as the airway pressure at which an audible oropharyngeal leak is detected during a standardized leak test.

Immediately after successful laryngeal mask placement, before the start of surgery

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
First-attempt insertion success
Tijdsspanne: During initial laryngeal mask insertion

Proportion of participants in whom effective ventilation is achieved after the first insertion attempt of the assigned laryngeal mask.

During initial laryngeal mask insertion
Overall insertion success
Tijdsspanne: During laryngeal mask insertion, up to 3 attempts

Proportion of participants in whom effective ventilation is achieved with the assigned laryngeal mask within the maximum number of insertion attempts permitted by the study protocol.

During laryngeal mask insertion, up to 3 attempts
Laryngeal mask insertion time
Tijdsspanne: During laryngeal mask insertion

Time in seconds from introduction of the assigned laryngeal mask into the mouth until establishment of effective ventilation.

During laryngeal mask insertion
Number of insertion attempts
Tijdsspanne: During laryngeal mask insertion

Number of attempts required to achieve successful placement and effective ventilation with the assigned laryngeal mask.

During laryngeal mask insertion
Need for additional airway maneuvers
Tijdsspanne: During laryngeal mask insertion

Proportion of participants requiring additional maneuvers to achieve satisfactory placement and ventilation.

During laryngeal mask insertion
Peak inspiratory pressure
Tijdsspanne: At 5 and 30 minutes after successful laryngeal mask placement

Peak inspiratory airway pressure measured in cmH2O during mechanical ventilation.

At 5 and 30 minutes after successful laryngeal mask placement
End-tidal carbon dioxide
Tijdsspanne: At 5 and 30 minutes after successful laryngeal mask placement

End-tidal carbon dioxide (EtCO2) measured during mechanical ventilation.

At 5 and 30 minutes after successful laryngeal mask placement
Heart Rate
Tijdsspanne: At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement

Heart rate will be recorded in beats per minute (bpm).

At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement
Blood staining on the laryngeal mask
Tijdsspanne: Immediately after device removal

Presence of visible blood staining on the laryngeal mask after removal.

Immediately after device removal
Postoperative sore throat
Tijdsspanne: At 1 and 24 hours after surgery

Presence of patient-reported sore throat following general anesthesia.

At 1 and 24 hours after surgery
Postoperative hoarseness
Tijdsspanne: At 1 and 24 hours after surgery

Presence of patient-reported hoarseness following general anesthesia.

At 1 and 24 hours after surgery
Airway-related adverse events
Tijdsspanne: From laryngeal mask insertion through postoperative observation, assessed up to 24 hours after surgery

Occurrence of airway-related adverse events, including laryngospasm and clinically evident regurgitation.

From laryngeal mask insertion through postoperative observation, assessed up to 24 hours after surgery
Arterial Pressure
Tijdsspanne: At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement

Arterial pressure will be recorded in mmHg.

At baseline, immediately after successful laryngeal mask placement, and at 5 and 30 minutes after placement

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 oktober 2026

Primaire voltooiing (Geschat)

1 juni 2027

Studie voltooiing (Geschat)

1 juli 2027

Studieregistratiedata

Eerst ingediend

16 september 2026

Eerst ingediend dat voldeed aan de QC-criteria

16 september 2026

Eerst geplaatst (Werkelijk)

23 september 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

7 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

2 oktober 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren